Why the study?
Does TF-TAVR compared to SAVR improve in-hospital outcomes in patients aged 65-74 years with aortic valve stenosis?
Does TF-TAVR compared to SAVR improve in-hospital outcomes in patients aged 65-74 years with aortic valve stenosis?
In patients aged 65-74 years with aortic stenosis, TF-TAVR and SAVR have similar in-hospital mortality, but TF-TAVR is associated with more pacemaker implantations and less delirium.
TF-TAVR was associated with similar in-hospital mortality but more pacemakers and less delirium versus SAVR; leaves open confirmation in randomized trials for patients aged 65-74.
AIMS: Randomised trials comparing transcatheter aortic valve replacement (TAVR) with surgical aortic valve replacement (SAVR) have included mainly elderly patients >80 years. The authors investigated comparative in-hospital outcomes of younger patients <75 years undergoing transfemoral (TF) TAVR or isolated SAVR. METHODS AND RESULTS: A total of 6,972 patients aged 65-74 years undergoing TF-TAVR or SAVR between 2013 and 2014 were identified from the observational German Quality Assurance Registry on Aortic Valve Replacement (AQUA), which comprises all TAVR and SAVR procedures performed in Germany. Analyses were performed for the overall unmatched cohort as well as for 1,388 propensity-matched patients. Overall, 82.4% of patients <75 years needing treatment for aortic valve stenosis received SAVR. Patients undergoing TF-TAVR were older and had more comorbidities with higher predicted risk of death. After propensity-matching, in-hospital mortality (1.3% vs. 1.9%, p=0.39), neurologic complications (1.0% vs. 2.1%, p=0.09), and myocardial infarctions (0 vs. 0.3%, p=0.16) were not different after TF-TAVR or SAVR. Postoperative delirium was more frequent after SAVR (8.9% vs. 2.4%, p<0.001), whereas the need for new pacemaker was 4 times higher after TF-TAVR (13.3% vs. 3.5%, p<0.001). CONCLUSIONS: Younger patients <75 years undergoing TF-TAVR or SAVR had similar outcomes with the exception of more frequent need for new pacemaker implantation and less frequent incidence of post-operative dialysis and delirium in TF-TAVR patients. Whether these similar in-hospital outcomes are replicable in the longer-term events in TF-TAVR and SAVR remains to be proven in future studies.
No takes yet. Share an insight, caveat, or question.
Eggebrecht et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: